Higher carfilzomib dose induced durable response in multiple myeloma

  • July 29, 2014

A higher dose of carfilzomib induced a high overall response rate and “a remarkable duration of response” in patients with relapsed or refractory multiple myeloma, according to results of a phase 2 study.

The higher-dose regimen also demonstrated a manageable toxicity profile, although grade 3 and grade 4 adverse events related to treatment included heart failure and hypertension.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

  • Meeting News Coverage
  • OSN meeting
  • Kiawah Eye 2014
  • Read live onsite coverage from the Kiawah Eye meeting in Kiawah, S.C.
  • Human microbiome
  • microbiome 4_25_14
  • A 'How To' Guide
  • A trio of researchers authors “how to” guide for gastroenterologists navigating the rapidly expanding field of human microbiome research.
More »
More »
  • SLIT agents are trending
  • SPOLIGHT on SLIT
  • Sublingual immunotherapy
  • Healio.com presents the latest in sublingual immunotherapy FDA and research news.
More »
More »
More »